5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.83▲ | 2.79▲ | 2.77▲ | 2.52▲ | 2.17▲ |
MA10 | 2.82▲ | 2.77▲ | 2.74▲ | 2.35▲ | 2.44▲ |
MA20 | 2.79▲ | 2.75▲ | 2.62▲ | 2.10▲ | 3.05▼ |
MA50 | 2.75▲ | 2.52▲ | 2.42▲ | 2.44▲ | 5.86▼ |
MA100 | 2.73▲ | 2.41▲ | 2.17▲ | 3.25▼ | 5.53▼ |
MA200 | 2.62▲ | 2.14▲ | 2.13▲ | 5.42▼ | 5.79▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.002▲ | 0.000▲ | 0.012▲ | 0.120▲ | 0.077▲ |
RSI | 63.290▲ | 65.011▲ | 67.051▲ | 67.606▲ | 40.085▼ |
STOCH | 81.162▲ | 69.091 | 71.078 | 81.593▲ | 27.174 |
WILL %R | -5.263▲ | -1.818▲ | -15.385▲ | -5.042▲ | -52.471 |
CCI | 114.945▲ | 142.338▲ | 107.364▲ | 140.716▲ | -7.323 |
▲ GAP | $LRMR Open Gap Up %2 | Set Alert |
Wednesday, April 30, 2025 04:00 AM
FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking ...
|
Wednesday, April 16, 2025 05:00 PM
1 Day LRMR 3.80% DJIA -1.33% Russell 2K 0.92% Health Care/Life Sciences 0.59% ...
|
Sunday, April 13, 2025 05:00 PM
March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 2.72 | 2.86 | 2.5205 | 2.86 | 3,094,605 |
30/04/25 | 2.40 | 2.92 | 2.395 | 2.65 | 3,494,913 |
29/04/25 | 2.34 | 2.46 | 2.29 | 2.39 | 750,638 |
28/04/25 | 2.33 | 2.41 | 2.23 | 2.35 | 692,833 |
25/04/25 | 2.33 | 2.37 | 2.265 | 2.33 | 628,663 |
24/04/25 | 2.26 | 2.37 | 2.23 | 2.37 | 676,457 |
23/04/25 | 2.47 | 2.51 | 2.18 | 2.26 | 1,416,312 |
22/04/25 | 2.04 | 2.44 | 2.00 | 2.38 | 2,331,948 |
21/04/25 | 1.88 | 2.0589 | 1.865 | 2.01 | 1,159,098 |
17/04/25 | 1.86 | 1.97 | 1.86 | 1.91 | 1,094,996 |
|
|
||||
|
|
||||
|
|